Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 30 min ago
Peer-reviewedCC BY-NC-ND 4.0Cardiovascular Drugs and Therapy

Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis

  1. 1Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong P. R. China
  2. 2Department of Cardiology, The First People’s Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Guangdong, Foshan, Guangdong P. R. China

Abstract

Objectives: No pharmacotherapies effectively halt the progression of calcific aortic valve stenosis (CAVS). We leveraged multi-omic analyses to identify potential drug targets of CAVS.

Methods: We integrated druggable genome with cis-expression quantitative trait locus (eQTLs) data from the eQTLGen Consortium to identify instrumentable genes. Two independent genome-wide association study (GWAS) datasets for CAVS were used for Mendelian randomization (MR) analysis (Finngen dataset for discovery, a genome-wide meta-analysis cohort for replication). Genes showing significant associations in both cohorts underwent Bayesian colocalization, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Candidates were verified by proteomic analysis (liquid chromatography-tandem mass spectrometry, LC-MS/MS) and immunohistochemical (IHC) analysis of human aortic valves. Additionally, a phenome-wide association study (PheWAS) was conducted to assess the horizontal pleiotropy. A reverse MR analysis was performed to assess potential reverse causality.

Results: Seven druggable genes were significantly associated with CAVS in both cohorts. Among these, C4A and C4B exhibited robust colocalization evidence (both posterior probabilities PP.H4 > 80%). While LC-MS/MS confirmed the significant upregulation of C4A and C4B at the protein level (fold changes of 1.58 and 1.51, respectively; p < 0.05), only C4B was established as a risk factor for CAVS (odds ratio: 1.04, 95% confidence interval: 1.03–1.06, p = 3.49 × 10− 9 in the replication phase). The reverse MR analysis validated the causal effect, and the PheWAS analysis revealed no significant association with broad phenotypes. IHC localized C4B expression predominantly in aortic valve interstitial cells, with significantly higher integrated density in calcific valves (1916.95 ± 1118.89 vs. 502.34 ± 474.27; p = 0.025).

Conclusion: Our study offers a genetically anchored therapeutic hypothesis involving the immune-complement system and identifies C4B as a prioritized candidate with therapeutic potential for CAVS.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10557-026-07896-1.

Related

  1. Identification of genetically supported candidate therapeutic targets for angina pectoris using mendelian randomization
    Zixuan Wang, Dexin Wang, Longke Ran +2
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Single-cell eQTL Mendelian randomization reveals the monocyte-associated PRKCB–CTSL axis as a candidate regulatory pathway and potential therapeutic target in rheumatoid arthritis
    Pengli Wang, Guohang Shen, Wenhua Liao +6
    Clinical RheumatologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Abdominal Adiposity and Lacunar Stroke: A Mendelian Randomization Mediation Study
    M. Guo, L. Cong, Z. Liu
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  4. Genetically Proxied SGLT2 Inhibition and Risk of Epilepsy: A Mediation Mendelian Randomization Study of Circulating Metabolites
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Stroke and brain white/gray matter alterations : A Mendelian randomization investigation
    Xiaoyong Wu, Longtao Yang, Weijia Xu +1
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
BibTeX
@article{li2026complement,
  title = {{Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis}},
  author = {Weijie Li and Ting Zhou and Songyuan Luo and Jiaohua Chen and Zejia Wu and Wenhui Lin and Xiaolu Hu and Xinyue Yang and Jie Li and Zhaoyan Xu and Jianfang Luo},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  month = jul,
  doi = {10.1007/s10557-026-07896-1},
  url = {https://doi.org/10.1007/s10557-026-07896-1},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis
AU  - Weijie Li
AU  - Ting Zhou
AU  - Songyuan Luo
AU  - Jiaohua Chen
AU  - Zejia Wu
AU  - Wenhui Lin
AU  - Xiaolu Hu
AU  - Xinyue Yang
AU  - Jie Li
AU  - Zhaoyan Xu
AU  - Jianfang Luo
PY  - 2026
DA  - 2026/07/07
JO  - Cardiovascular Drugs and Therapy
DO  - 10.1007/s10557-026-07896-1
UR  - https://doi.org/10.1007/s10557-026-07896-1
AB  - Objectives: No pharmacotherapies effectively halt the progression of calcific aortic valve stenosis (CAVS). We leveraged multi-omic analyses to identify potential drug targets of CAVS.  Methods: We integrated druggable genome with cis-expression quantitative trait locus (eQTLs) data from the eQTLGen Consortium to identify instrumentable genes. Two independent genome-wide association study (GWAS) datasets for CAVS were used for Mendelian randomization (MR) analysis (Finngen dataset for discovery, a genome-wide meta-analysis cohort for replication). Genes showing significant associations in both cohorts underwent Bayesian colocalization, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Candidates were verified by proteomic analysis (liquid chromatography-tandem mass spectrometry, LC-MS/MS) and immunohistochemical (IHC) analysis of human aortic valves. Additionally, a phenome-wide association study (PheWAS) was conducted to assess the horizontal pleiotropy. A reverse MR analysis was performed to assess potential reverse causality.  Results: Seven druggable genes were significantly associated with CAVS in both cohorts. Among these, C4A and C4B exhibited robust colocalization evidence (both posterior probabilities PP.H4 > 80%). While LC-MS/MS confirmed the significant upregulation of C4A and C4B at the protein level (fold changes of 1.58 and 1.51, respectively; p < 0.05), only C4B was established as a risk factor for CAVS (odds ratio: 1.04, 95% confidence interval: 1.03–1.06, p = 3.49 × 10− 9 in the replication phase). The reverse MR analysis validated the causal effect, and the PheWAS analysis revealed no significant association with broad phenotypes. IHC localized C4B expression predominantly in aortic valve interstitial cells, with significantly higher integrated density in calcific valves (1916.95 ± 1118.89 vs. 502.34 ± 474.27; p = 0.025).  Conclusion: Our study offers a genetically anchored therapeutic hypothesis involving the immune-complement system and identifies C4B as a prioritized candidate with therapeutic potential for CAVS.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10557-026-07896-1.
SN  - 0920-3206
SN  - 1573-7241
ER  -